Colleen Shalby is a reporter for the Los Angeles Times. She has covered education, the pandemic, the vaccine rollout and breaking news throughout California. She was part of the team that was a ...

Trevogrumab is under clinical development by Regeneron Pharmaceuticals and currently in Phase II for Obesity. According to GlobalData, Phase II drugs for Obesity have a 29% phase transition success ...

With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a ...

Regeneron Pharmaceuticals Inc.'s executives and board members overstated its key eye treatment’s average selling price, prompting a Department of Justice enforcement action and exposing the drugmaker ...

Your biospecimen will be sent to the Regeneron Genetics Center for genetic sequencing, then stored for future analysis. With something as sacred as your genetic material in its hands, Truveta and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

Cali is definitely supposed to be her name.” Baby naming consultant Colleen Slagen says she received about 20 inquiries from parents considering changing their baby's names in 2024.

Friends tell us the victim was 34-year-old Colleen Lischwe. A GoFundMe has raised around $15,000 for Lischwe as of Thursday afternoon. Lischwe was more than just a coach. Friends and colleagues ...

Colleen Lischwe, the head men’s and women’s water polo coach at McKendree University, died Wednesday in an automobile accident. She was 34 years old. The university confirmed the death on ...

Investing.com -- UBS has downgraded Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to "Neutral" from "Buy" given uncertainty around its key Eylea franchise. Brokerage slashed price target to $738 ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ...